Confirmatory Study of DSP-5423P in Patients With Schizophrenia

Trial Profile

Confirmatory Study of DSP-5423P in Patients With Schizophrenia

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Mar 2017

At a glance

  • Drugs Blonanserin (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Sumitomo Dainippon Pharma
  • Most Recent Events

    • 21 Jul 2016 Planned primary completion date changed from 1 Apr 2018 to 1 Dec 2018.
    • 08 Jul 2016 Planned number of patients changed from 360 to 501.
    • 01 Feb 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top